Continuous bioprocessing technologies, such as the XCell ATF system adopted by Enzene Biosciences, are improving monoclonal antibody manufacturing by enabling higher productivity, reduced costs, and smaller facility footprints compared to traditional fed-batch processes. Continuous manufacturing allows real-time monitoring leading to better product quality control, decreases carbon emissions by up to 54%, and lowers cost of goods by up to 80%. This process intensification is driving industry momentum toward more sustainable and flexible biologics production models.